BioNTech Investor Day Presentation Deck

RiboCytokines Designed to overcome limitations of recombinant cytokine therapy Systemic delivery ● • Backbone optimized and nucleoside-modified mRNA encoding cytokine fused to human albumin Liver-targeting LNP formulation with intravenous delivery Encoded cytokines translated in body cells and secreted Designed for optimized safety, tolerability and dosing Prolonged serum half-life High bioavailability Lower and less frequent dosing Lower toxicity ● ● ● , lipid nanoparticle; PK, pharmacokinetic; IL-2, Interleukin-2; IL7, Interleukin-7; UTR, untranslated region RiboCytokine® is a registered trademark of BioNTech. Lipid nanoparticle (LNP) Cap 30 BOB SPO Lipids Serum concentration 5' UTR RiboCytokine RNA Cytokine-Albumin NUM PK profile TH Time RiboCytokines Recombinant cytokine RiboCytokine 3' UTR AAA BIONTECH 143

View entire presentation